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Abstract
Background: The Symptom Assessment and Management (SAM) program is a structured, online, nurse-supported intervention
to support symptom self-management in people receiving adjuvant chemotherapy post surgery for breast or colorectal cancer.
Objective: The objective of this study was to describe the development, implementation strategy, and evaluation of the SAM
system.
Methods: The development of the SAM program involved 3 phases. In phase 1, the web app was developed through consultation
with consumers and clinicians and of the literature to ensure that the system was evidence-based and reflected the realities of
receiving treatment and supporting patients through treatment. In phase 2, 7 participants recorded the severity of 6 symptoms
daily over the course of 1 cycle of chemotherapy. In phase 3, 17 participants recorded their symptoms daily over the course of 3
cycles of chemotherapy. Once symptoms were recorded, participants received immediate feedback on the severity of their
symptoms and self-management recommendations, which could include seeking immediate medical attention. Data on quality
of life, symptom burden, anxiety and depression, distress, and self-efficacy were collected during treatment; participants’
perceptions of the SAM program were evaluated following participation via interview.
Results: The outcomes of the SAM project include the development of a system that is reliable and easy to use and navigate.
Participants reported benefits related to using the SAM program that included feeling more in control of managing their symptoms
and feeling reassured. Engagement with the system on a daily basis was variable, with some participants completing the symptom
tracker daily and others engaging some of the time. The feedback from all participants was that the system was easy to navigate
and the information was relevant and supportive.
Conclusions: The SAM program has the potential to enhance the management of symptoms for people receiving chemotherapy
treatment. The system creates an accurate repository of symptoms that can be accessed easily and highlight patterns in symptom
experience. These can be shared with clinicians, with patient permission, to inform and support treatment plans. The potential to
predict the risk of developing severe symptoms can be developed to anticipate the need for care and support. Further considerations
on how to increase engagement with the system, the value of the system for people diagnosed with other tumor types and treatment
regimes, and the incorporation of the system into everyday clinical practice are needed.
(JMIR Cancer 2020;6(2):e22825) doi: 10.2196/22825
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Chemotherapy is a core component of cancer care for many
people diagnosed with cancer and can be used as an adjuvant
treatment, which means chemotherapy is an additional cancer
treatment given after the primary treatment, usually surgery, to
lower the risk that the cancer will return. There are a range of
symptoms commonly experienced by people receiving
chemotherapy, including pain, fatigue, trouble sleeping, nausea,
vomiting, distress, anxiety, and depression [1]. The experience
of symptoms can have an impact on the ability to adhere to
treatment regimens and on quality of life [2,3]. In addition, the
toxic effects of chemotherapy can be serious and
life-threatening; for example, dehydration following vomiting
and/or diarrhea and infection following leukopenia.
Chemotherapy is most often delivered in the outpatient setting
and the majority of associated side effects are managed in the
community setting. The ability to communicate with health care
providers in a timely way about symptoms that are impacting
daily functioning, have become moderate or severe, or are
prolonged is important to promote effective self-management
and prevent hospitalization, or, in the case of severe or
prolonged symptoms, advise on the need for urgent attention
[1,2,4].
Technology can facilitate both the monitoring of symptoms and
communication between patients and health care providers, and
there has been a rapid increase in the number of systems in
development; however, many require further development in
order to enhance their usability and clinical integration [5], and
few studies have been conducted in cancer settings [6].
An increasing number of mobile apps have been designed to
support cancer care. Charbonneau et al [7] found 123 digital
health options specific to cancer patients. These apps provide
a variety of services for those in the cancer community. The
apps support self-reporting and home monitoring of symptoms
associated with cancer treatment [2,8-14] and report toxicities
directly to the provider [2,8-12,14], as well as provide
disease-specific monitoring [10,11], monitoring during active
phases of cancer care [2,8,9,14] or during hospice stays [12],
evidence-based education or self-care advice based on patient
input to the system [2,12], and/or community cancer resources
[2,15].
The web app developed and implemented in this study, the
Symptom Assessment and Management (SAM) system,
combined all of these features with the addition of an alert
system. Based on patient scores, or levels of toxicity, alerts were
generated ranging from evidence-based education to contact
with providers to emergency assistance. We believe that the
web app, developed in collaboration with consumers and health
care providers, provides a comprehensive platform for people
receiving adjuvant chemotherapy for breast or colorectal cancer
to access information, assess and chart a range of symptoms,
and receive real-time self-care advice.
Methods
Study Aim
The aim of the pilot study was to develop and implement a SAM
web app for patients receiving chemotherapy as adjuvant
treatment after surgery for breast or colorectal cancer.
Participants did not have a diagnosis of active cancer.
Participants were prompted by the mobile, web-based system
to assess symptoms during treatment and they were provided
with evidence-based real-time recommendations to support their
self-management.
Study Design
A mixed methods design was employed involving 3 phases: (1)
phase 1, development of the web app, (2) phase 2, pilot
involving one cycle of chemotherapy, and (3) phase 3,
intervention over 3 cycles of chemotherapy.
Phase 1: Development Phase
In the development phase, a review of the literature related to
best practice of symptom management was conducted to develop
alert levels for symptom severity and self-care messages. The
guidelines and self-management documents highlighted the
most commonly reported symptoms, when patients need to
contact a clinician for advice or seek emergency support and
self-management advice on managing symptoms. Following
the review, consultation with consumers who had experience
of breast or colorectal cancer and meetings with clinicians were
held to further inform the selection of symptoms to be included
in the system, the development of the alert algorithms and the
content of the self-care messages. The symptoms of nausea,
vomiting, diarrhea, constipation, temperature, mouth and throat
sores (mucositis), neuropathy (numbness in hands and feet),
fatigue, and distress were selected. An external company was
employed to design and create the interactive web platform, the
SAM platform. Three meetings were held with the developers
to discuss the content to be included as supplied by the research
team, usability features of the web app, presentation of the web
app and pretesting. In addition to tracking symptoms on a daily
basis, the web app provided participants with relevant phone
numbers, self-care advice, access to evidence-based resources,
and a summary page of symptoms (my symptom history).
Participants were also reminded that the site was “not monitored
24/7 and should not be used as a replacement for medical
appointments.” An advisory committee was established and
included clinicians from the medical oncology team, nursing
representatives, the research team, and three consumer
representatives who had experienced cancer and received
chemotherapy. Two meetings were held to report on progress
and seek advice on recruitment strategies.
Phase 2: Pilot
In Phase 2, 7 participants were asked to record their symptoms
daily on the web app for 1 chemotherapy cycle using either a
personal computer, iPad (Apple Inc), or smartphone. Participants
were invited to record their temperature using a thermometer
provided by the research team to check whether they had a
raised temperature, which could be indicative of an infection.
Participants completed questionnaires at baseline (prior to the
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chemotherapy cycle) and again at the commencement of cycle
2 (approximately day 14 for colorectal cancer patients or
approximately day 21 for breast cancer patients) to evaluate
quality of life, symptom burden, mental health, and self-efficacy.
Participants completed an interview at the end of the cycle of
chemotherapy. The key aim of this phase was to ensure that the
web app was functional from a user perspective, data were
collected and stored as planned, and the alert system did not
create undue distress for participants or additional and
unnecessary demands on health care staff.
Phase 3: Intervention
In phase 3, 17 participants recorded symptoms on the web
platform over 3 chemotherapy cycles. Participants were also
invited to record their temperature using the thermometer
provided to check whether they had a raised temperature, which
could be indicative of an infection. During this phase,
participants completed questionnaires at baseline (prior to the
chemotherapy cycle) and at the commencement of cycles 2, 3,
and 4. Interviews were conducted at the end of cycle 3. The aim
of this phase was to explore the usability and utility of the site
over a longer period of time, including the number of alerts
generated and the actions taken as a result of the alerts
generated.
Ethics
The study received approval from the human research ethics
committee at the hospital as well as the university ethics
committee.
The SAM System
The web-based system comprised four functions: (1) to monitor
symptoms experienced on a daily basis or anytime a participant
wanted to assess their symptoms, (2) to provide immediate
feedback on self-care actions to be taken based on the data
entered, (3) to map symptoms on a graph over time that could
be reviewed by the participant or provided to clinicians to
review, and (4) to provide a repository of evidenced based
information on key symptoms for further reading and
consultation.
The decision to build a web-based app over a native app was
driven primarily by the goals of the system and secondly by
cost. The web-based app was able to meet all of the study needs
and was able to be viewed and used across a range of devices
(desktops computers, laptops, iPads, and smartphones). The
research team believed that a native app would not add any
benefit in relation to aesthetics or functionality but would risk
compromising accessibility and would cost substantially more
to create. A screenshot of the log-in page as it appears on a
smartphone and a tablet are presented in Multimedia Appendices
1 and 2, and additional screenshots, including examples of
self-care messages, are presented in Multimedia Appendices
3-5.
Daily Symptom Monitoring
The system allowed for real-time symptom monitoring and
management of nausea, vomiting, diarrhea, constipation, mouth
and throat sores (mucositis), neuropathy (numbness in hands
and feet), fatigue, and distress in patients who had surgery for
early breast or colorectal cancer. A scale from 0 to 10 was
created for each symptom, allowing participants to slide a cursor
up and down the scale. On completion of the scales, a series of
self-care messages were sent back to guide self-care, and within
these messages was the alert level that the scores had generated.
The algorithms differed by symptom, but self-care advice was
either green (no or mild symptoms), amber (indicating an area
of concern), or red (indicating serious concern and the need to
take action). For example, an amber alert would advise
participants to contact their medical oncology team or general
practitioner during business hours or, if the participant was
concerned, to visit their closest emergency department after
hours; a red alert would suggest that the participant go to their
closest emergency department for immediate assistance. As per
the study protocol, red alerts were forwarded to the medical
oncology clinical nurse manager (CNM) within 1 to 3 days of
being received by the research team, in case additional follow-up
was required. The symptoms were mapped onto graphs
accessible on a separate page on the site and these allowed
participants to view the trajectory of symptoms over time.
Library of Resources
A library of resources was generated to include links to one or
more evidence-based sites for each symptom. The resource page
was referred to in the self-care messages where appropriate and
was accessible at all times to participants to access when
necessary. The contact numbers of key personnel and groups
were displayed in two places on the site: on the home page and
on the self-management report page following the entry of
symptoms.
Population and Setting
Participants were individuals who had received a diagnosis of
breast or colorectal cancer, completed surgery, and were
scheduled to receive adjuvant chemotherapy at a tertiary hospital
in a metropolitan area. Additional inclusion criteria were that
participants were aged 18 years or older; receiving a minimum
of 3 cycles of chemotherapy on an outpatient basis; able to read,
write, and speak English sufficiently well to participate in data
collection; deemed by a member of the health care team to be
physically and psychologically fit to participate in data
collection; able to provide written consent (hard copy or
electronic); and willing and able to use their own computer,
iPad, or smartphone with internet access to complete the study.
The exclusion criterion was a prior experience of chemotherapy.
Participant Recruitment
Participating medical oncologists and the CNM identified
eligible participants by screening patient referrals and medical
history prior to chemotherapy clinics each week. Those eligible
to participate were given information about the study by the
participating medical oncologists or CNM and offered a copy
of the participant information and consent form to review. For
patients who agreed, their details (name, phone number, date
of first chemotherapy cycle) were forwarded to the research
assistant and contact was made following a chemotherapy
education session. Consenting participants were shown face to
face how to access and navigate the site and/or emailed
information to help them access the SAM website and a link to
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complete the surveys at each time point. Prior to the start of
phase 1, medical oncology and nursing staff were invited to
attend a short training session on the recruitment process and
how the SAM web portal would be used by participants. The
goal was to recruit up to 10 people in phase 2 to test the system
across one cycle of chemotherapy and to recruit up to 40 people
in phase 3. Because this was a feasibility study without a
comparison group, the figures were based on how many
participants it seemed reasonable to recruit within the study
time frame and based on a review of the outpatient list of
potentially eligible patients over the preceding month.
Participant Questionnaires
Participants completed the Functional Assessment of Cancer
Therapy-Breast (FACT-B) [16] and Functional Assessment of
Cancer Therapy-Colorectal (FACT-C) [17] cancer scales to
measure quality of life, the Rotterdam Symptom Checklist
(RSCL) to measure symptom burden [18], the Hospital Anxiety
and Depression Scale (HADS) to assess mental health [19,20],
and the Strategies Used by Patients to Promote Health (SUPPH)
[21,22] to measure self-efficacy. The FACT-B has been assessed
as appropriate for use in oncology clinical trials, as well as in
clinical practice. Ease of administration, brevity, reliability,
validity, and sensitivity to change have been reported [16].
Significant sensitivity to change in the performance status rating
was demonstrated for the FACT-B total score, the physical
well-being subscale, the functional well-being subscale, and
the breast cancer subscale. An alpha coefficient (internal
consistency) for the FACT-B total score has been reported to
be high (α=.90), with subscale alpha coefficients ranging from
.63 to .86. There is evidence to support test-retest reliability, as
well as convergent, divergent, and known groups validity. The
reliability and validity of the FACT-C was reported across three
samples that differed based on the extent of disease and ethnicity
[17]. Across the samples, adequate reliability and validity were
demonstrated for the FACT-C. Internal consistency analyses
across the samples yielded alpha coefficients above .85 for the
FACT-C total score. The FACT-C was able to distinguish
among patients of different functional categories, particularly
between ambulatory patients and patients who required bed rest
for some period of time during the day. For patients whose
functional status worsened, their quality of life worsened
compared with patients whose functional status stayed the same
or got better, indicating that the FACT-C is sensitive to changes
in functional status.
For the RSCL, the reliability of the three subscales is high, with
alpha coefficients ranging from .80 to .87 on the physical
symptom distress scale, .85 to .94 on the psychological symptom
distress scale, and .86 to .95 on the activity level scale [23]. The
clinical validity of the RSCL is reported as satisfactory. The
physical distress scales, subscales, and individual physical items
differentiate between disease and treatment states as well as
moments of treatment process. The psychological scale
differentiates between cases and noncases [23].
The HADS has demonstrated satisfactory psychometric
properties across a range of groups: in primary care [20], with
cognitively intact patients in nursing homes [24], with inpatients
with cancer [25], and in the general population [20,26].
The SUPPH was developed to measure patients’ confidence in
carrying out self-care strategies [21]. Good initial psychometric
properties were found in patients receiving either cancer
chemotherapy or hemodialysis. The alpha coefficients were
well above the desired criterion of .70. Test-retest and
generalizability estimates for the SUPPH were high [22].
Measures were completed at baseline and at the commencement
of cycle 2 (phases 2 and 3) and cycles 3 and 4 (phase 3 only).
Participants were emailed a survey link at each time point, which
allowed them to complete the questionnaires through the
Qualtrics online survey platform [27]. This ensured that
participants received their questionnaires independent of clinic
visits and it allowed questionnaires and reminders to be emailed
directly to participants by the research team without the need
to involve clinical staff. If requested, paper questionnaires were
mailed to participants who preferred to complete the
questionnaires in hard copy.
Interviews
Participants were invited to participate in a semistructured phone
interview to explore their experiences using the web platform.
The question guide used in the interviews was developed by
the research team in consultation with the consumer advocates
and advisory committee. Interviews were transcribed and
analyzed using content and thematic analysis to identify
common themes. Questions addressed the relevance of items
in the scale (symptoms), the self-care messages, the resources
section, and the symptom graphs; the experience of any
symptoms not included in the scale; and feedback on the layout
of the site and navigation and recommendations to improve the
site.
Data Analysis
Data from the demographic questionnaire and questionnaires
retrieved from Qualtrics were saved for analysis using SPSS
software (IBM Corp). Data analysis explored changes over time
in relation to quality of life, symptom burden, mental health,
and self-efficacy. Phone interviews were transcribed using
NVivo software (QSR International) and analyzed using content
and thematic analysis. Content analysis of the comments created
within the system were undertaken where they were generally
short and supported the reason for recording a certain symptom
severity. Thematic analysis [28] was undertaken with the
interview data involving the stages of familiarization, coding,
generating initial themes, reviewing themes, designing and
naming themes, and writing up.
Results
Sample Characteristics
In total, 44 individuals were approached to participate in the
study and 24 of them consented to participate. The sample
comprised 12 women who had been diagnosed with breast
cancer (phase 2, n=3; phase 3, n=9) and 12 people diagnosed
with colorectal cancer (phase 2, n=4; phase 3, n=8). No
participant had active disease or was scheduled to receive
adjuvant chemotherapy. Table 1 sets out the demographic
details.
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Table 1. Sociodemographic characteristics of study participants.
Total (N=24)Phase 3 (n=17)Phase 2 (n=7)Characteristics
Age (years)
1 (4)1 (6)0 (0)≤29, n (%)
6 (25)4 (24)2 (29)30-49, n (%)
17 (71)12 (71)5 (71)≥50, n (%)
55.8 (13.8)55.2 (14.8)57.4 (11.7)Mean (SD)
Cancer diagnosis, n (%)
12 (50)9 (53)3 (43)Breast
12 (50)8 (47)4 (57)Colorectal
Gender, n (%)
5 (100)5 (29)0 (0)Male
19 (100)12 (71)7 (100)Female
Marital statusa, n (%)
14 (58)10 (59)4 (57)Married/partnered
9 (38)7 (41)2 (29)Not partnered (single/separated/divorced)
Country of birth, n (%)
15 (63)10 (59)5 (71)Australasia
6 (25)5 (29)1 (14)Europe
1 (4)0 (0)1 (14)South Africa
2 (8)2 (12)0 (0)Asia
Highest level of education, n (%)
9 (38)5 (29)4 (57)Completed high school
4 (17)4 (24)0 (0)Trade or technical and further education certificate
11 (46)8 (47)3 (20)Tertiary qualification/s
Employment statusb, n (%)
6 (25)5 (29)1 (14)Full-time
8 (33)6 (35)2 (29)Part-time/casual
2 (8)1 (6)1 (14)Homemaker
8 (33)5 (29)3 (43)Retired/not working
aValues do not always total 100% due to missing responses for some variables.
bWithin 12 months prior to diagnosis.
Engagement with the Web Platform (SAM)
Visits to the Website and Completion of the Symptom
Tracker: Phase 2
The web analytics allowed tracking of the number of visits to
the website, pages visited, completion of the symptom tracker,
and dates for each. The number of times the symptom tracker
was completed in phase 2 ranged from 9 to 33 (days enrolled
in SAM ranged from 15 to 67 days). The number of missed
days ranged from 0 to 34 days, a completion rate that ranged
from 51% to 100% of days symptoms were recorded using the
symptom tracker, with an average completion rate of 78% of
days enrolled.
Based on feedback from the consumer group, we included an
option for participants to click a button on the homepage if they
had no symptoms to record—effectively a score of 0 across all
symptoms. Four participants in phase 2 used this option and
recorded 2, 3, 7, and 9 days, respectively, where they had “no
symptoms to record.”
Recording of Symptoms as Severe: Phase 2
Symptoms were recorded as being severe (8 or above) on
individual symptoms a total of 22 times: nausea (n=2), vomiting
(n=1), diarrhea (n=2), constipation (n=4), mucositis (n=1),
fatigue (n=8), and distress (n=4). In phase 2, 16 red alerts were
recorded: constipation (n=2), diarrhea (n=2), distress (n=5),
nausea (n=2), vomiting (n=5). The red alerts were generated by
5 of 7 (71%) phase 2 participants. Four people generated
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multiple red alerts: 1 participant generated 5 separate red alerts
for vomiting (n=3), constipation (n=1), and distress (n=1); 1
participant generated 4 separate red alerts for vomiting (n=2),
constipation (n=1), distress (n=1), and nausea (n=1); 2
participants generated 2 red alerts for distress (n=3) and diarrhea
(n=1); and one participant generated 1 red alert for vomiting
(n=1). In addition, 7 (44%) of the 16 reported red alerts also
contained at least 1 or 2 amber alerts for other symptoms,
including constipation (n=2), distress (n=4), fatigue (n=3), and
mucositis (n=1).
Generation of Red Alerts: Phase 2
The number of days between treatment and symptom severity
triggering a red alert varied between 0 (ie, the same day as
chemotherapy) and 11 days. Two of the red alerts also included
a report of the participant being admitted to hospital. In addition,
2 hospital admissions were reported following the generation
of an amber alert.
Visits to the Website and Completion of the Symptom
Tracker: Phase 3
In phase 3, the number of times the symptom tracker was
completed ranged from 21 to 106 times and days enrolled in
SAM ranged from 45 to 117 days. The number of missed days
ranged from 0 to 87 days, and completion rate ranged from 21%
to 100%, with an average of 59%. Nine participants used the
“no symptoms to report” button in phase 3 on between 1 and
10 days: 10 days (n=1), 5 days (n=2), 4 days (n=2), 3 days (n=1),
2 days (n=1), and 1 day (n=2).
Recording of Symptoms as Severe: Phase 3
Symptoms were recorded as being severe (8 or above) on
individual symptoms a total of 78 times: nausea (n=6), vomiting
(n=5), diarrhea (n=8), constipation (n=3), mucositis (n=8),
neuropathy (n=16), and fatigue (n=32). Three participants did
not record any symptoms of 8 or above and 4 participants only
recorded 1 symptom at one time point as 8 or above.
Generation of Red Alerts: Phase 3
The number of valid red alerts generated during phase 3 was
38: constipation (n=2), diarrhea (n=13), distress (n=5), nausea
(n=7), neuropathy (n=2), high temperature (n=2), and vomiting
(n=7). As per the study protocol, these red alerts were forwarded
to the medical oncology CNM within 1 to 3 days of being
received by the research team in case additional follow-up was
required. Two additional red alerts were excluded after being
identified as incorrect entries (ie, temperature recorded as 367
instead of 36.7 and 63.8 instead of 36.8).
The 38 red alerts were generated by 12 participants. Seven
participants generated multiple red alerts: 6 alerts (n=2), 5 alerts
(n=2), 4 alerts (n=2), and 3 alerts (n=1). The remaining 5
participants each generated 1 alert. In addition, 15 (39%) of the
38 reported red alerts also contained between 1 and 3 amber
alerts for other symptoms: constipation (n=2), distress (n=6),
fatigue (n=5), mucositis (n=4), neuropathy (n=3), and vomiting
(n=3).
The number of days between treatment and symptom severity
triggering a red alert ranged between 0 (ie, the same day as
chemotherapy) and 26 days. Three participants also reported a
hospital visit and/or stay at the same time as their red alert. Two
of these participants also advised that their chemotherapy cycles
were delayed by 1 to 2 weeks due to neutropenia. Four hospital
admissions were reported following the recording of amber
alerts.
Use of Resource Pages
The resource pages were not accessed regularly by participants.
In phase 2, 4 participants accessed resource pages and in phase
3, 6 participants accessed resource pages. The participants who
accessed resource pages visited a variety of pages rather than
one or two pages. No link between symptom experience or
severity of symptoms and accessing resource pages was found.
Questionnaire Data for Phase 3 Participants
Mental Health: Anxiety and Depression
The frequency of self-reported levels of anxiety and depression
(Table 2) show that at each time period, the majority of phase
3 study participants were experiencing a clinical level of anxiety
and a borderline clinical level of depression, which increased
(from 53% to 70.5%) and decreased (from 80% to 47%),
respectively, over time. The statistical significance of these
changes in anxiety and depression could not be reliably
determined due to low frequencies across each of the 4 time
points.
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Table 2. Frequencies for mental health categories and median scores for physical and psychological symptom burden and self-efficacy at each time
point for phase 3 participants (n=17).
Time pointVariables
Pre cycle 4Pre cycle 3Pre cycle 2Baseline
Mental health, n (%)
Anxiety
2 (12)1 (6)2 (12)3 (18)Normal range
3 (17)3 (18)7 (41)5 (29)Borderline clinical
12 (71)13 (76)8 (47)9 (53)Clinical
17 (100)17 (100)17 (100)17 (100)Total
Depression
6 (35)3 (19)3 (18)2 (13)Normal range
8 (47)9 (56)14 (82)12 (80)Borderline clinical
3 (18)4 (25)0 (0)1 (7)Clinical
17 (100)16 (100)17 (100)15 (100)Total
Symptom burden, median score
48.044.040.036.0Physical symptom distress
13.012.011.513.0Psychological symptom distress
2.02.52.52.0Overall valuation of life
113.6117.1105.192.1Self-efficacy, median score
Symptom Burden
Median scores at each time point for physical symptom distress,
psychological symptom distress, and overall valuation of life
indicate that participants reported a relatively low level of
symptom distress and a good overall valuation of life across the
time points (Table 2). The level of physical symptom distress
did significantly increase over time (Friedman χ23=19.1, P<.001;
n=14) while the level of psychological symptom distress
(Friedman χ23=7.4, P=.06; n=16) and valuation of life (Friedman
χ23=2.7, P=.44; n=16) did not vary significantly over time.
Self-Efficacy
Reports of self-efficacy were relatively high among the phase
3 participants at each time point (Table 2). However, the
increase in median self-efficacy scores from baseline over the
treatment cycle was not statistically significant (Friedman
χ23=0.4, P=.94; n=12).
Quality of Life
Data on the participants’ quality of life, as measured by the
FACT-B (version 4) and FACT-C (version 4), were not reported,
as full scale scores for approximately 60% of participants at
each time point could not be calculated because of missing
values. Missing values were spread across a number of scale
items, although the item with the highest number of missing
responses concerned the participant’s satisfaction with their sex
life. Up to 58% of respondents opted not to respond to this item.
This may be because participants considered the issue too
personal to disclose or because they considered a response to
the item to be unrelated to their illness. Future studies of the
self-reported quality of life of persons undergoing cancer
treatment might consider using an alternative, shorter validated
and reliable measure and ensure that participants cannot opt out
of responding to items (eg, use a forced-choice survey format).
Interview Data
Fifteen interviews were completed: 4 in phase 1 and 11 in phase
2. The findings from phase 1 were comparable with those
identified in phase 2 and the combined data. The key findings
were ability to use technology and benefits of using the system
and recommendations.
Ability to Use Technology
Participants received training in accessing and using the site.
All described the training as adequate and the site as
straightforward and easy to use:
Oh definitely. Just basic. That was good. Yes. And
just so it was quick to go through it as well. And for
me with no computer skills that’s saying something.
[P204]
Participants accessed the site on a range of devices—computer,
smartphone, or tablet—and nearly all participants used the same
device throughout the study. Participants reported being able
to connect to the site easily, although many reported having
trouble activating the option to remain logged into the webpage.
Once this was explained, no further issues were reported.
No, nothing major. I forgot the passwords a couple
of times and got myself into a bit of a muck. But that
was my problem. But no I managed to get there.
[P218]
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Participants reported that the site was well designed,
straightforward, and easy to use. All participants described the
scale (0-10) as easy to navigate, and all participants stated that
they felt a scale was the best way to measure symptom severity,
rather than a method such as emojis.
I use them (emojis). I use them in my texts, and I use
them, but I’m not sure they are completely medically
appropriate. [P208]
Key Benefits of Using the System
All participants reported the key benefits of the system as being
made aware of their symptoms and changes in symptoms over
time, as well as being able to account for symptoms.
Basically it kept you where you were. What’s going
on, knowing all your symptoms, keeping up with
things and keeping up with you know the side effects.
Yeah that was important to me. I've noticed now
because I haven’t been using it. It’s hard to keep track
of where I’m at what’s happening. [P204]
Participants were required to enter data on the SAM site once
a day. Although data collected directly from the website suggests
not all participants completed daily entries for the duration of
the study period, everyone described a daily level of engagement
as repetitive but acceptable.
It’s repetitive of course but it is what it is. But I found
it not too hard to fill in. No not at all. [P206]
Remembering to log in was sometimes an issue, with
participants suggesting they either forgot or did not always feel
well enough. Even so, using the system did not appear to have
an impact on daily routines or cause distress.
Sometimes it was because I was feeling really rough
and other times it was that I basically forgot. I should
have done it…and I suppose if I hadn’t done it one
day I thought I might have thought ‘did I do it’? I
couldn’t remember whether I’d done it as well
sometimes. I suppose that sometimes I’d go in and
I’d do it—put my symptoms in and then I don’t think
it logged it because it kinda logged me out and I had
to log back in and then I’d repeat what I’ve just done.
[P221]
Participants mostly described remaining engaged with the
self-care messages that were returned and continued to see them
as positive and to read them.
I can’t remember the ones that popped up off the top
of my head but they were useful. It was like, it was
good to know. Oh yeah. Great I haven't been nauseous
today. That's nice. Like that was good, like positive
reinforcement that things are getting a bit easier. So
that was good. [P211]
Overall, participants were positive about the alert facility of the
system, reporting that they felt “secure” in the knowledge that
their data were being tracked and they had a record. Participants
were aware that their symptoms were not being monitored by
clinicians; however, they were aware that alerts would be
forwarded to the CNM, who in turn would make a note of the
alert on the patient’s file and follow them up as required. This
resulted in a follow-up call made to the participant or their
family, which was received positively.
My husband got a call from the medical oncology
nurse after I had been admitted to hospital. This gave
him relief that I was being followed up. [Pilot,
Respondent A]
As I say some people at the other end reacted when
it flagged up a possible problem so I was quite
impressed. [P206]
All participants interviewed described feeling reassured that
their symptoms were being tracked.
I found that the whole thing was very useful keeping
a track on myself as well as knowing where I’m at.
[P204]
The information was you know that it sort of
reassured me that things were going probably as they
should do. [P205]
Participants described having information collated in one place
and the ability to review patterns helpful.
Yes they were useful, they were a little bit um, what’s
the word. They would sort of ease your mind a wee
bit when you went through them to say well things
aren’t quite as bad as you might think they are. [P205]
Yeah I’ll go back and have a look and then I see the
little patterns. When you are worse and such, when
you come good you can follow it that way. [P207]
Several participants described following recommendations
generated in the daily symptom tracker to contact a clinician or
a medical oncology team member, or to visit the emergency
department based on the feedback.
Even with the green, I was more like oh okay I’ll take
that in note and I’ll suggest it to my specialist. [P204]
I think the three different colors (symptom tracker
web page) was definitely good. Obviously orange was
sort of like I’ve really got to pay attention. I did ring
the nurses a few times if I was getting a randomly
different side effect. [P211]
Yes. I had to go in—high temp...I think it did tell me
like bang—This is high. Like consult. Don’t wait for
the next day or see how you are in the morning.
[P207]
Once I hit the orange then it was like yeah I’ll give
them a call. So it was good to have that as a reference.
[P211]
A number of participants described the system as supporting
them to manage their symptoms more effectively:
Yes there would have been times where I went Ah
don’t worry I’ll feel okay I just won’t bother with my
temperature. Yeah. And I think that was a big eye
opener…So it made me go stop, rest and recheck
myself. [P204]
I think yeah the color coding thing, definitely. So if I
was in the orange or the red it definitely causes you
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to do something. It definitely causes you to action
something. So yes definitely in that sense. [P211]
The ability to assess symptoms over time was valued:
Just the fact that you can go back and just having a
little bit of a good look at the history you know that
sometimes you can’t quite remember sometimes. When
you had a bad day or something you can go back and
go you can see your peaks and troughs—these things
that you’ve selected. I’ve gone back and had a look
and see how it goes up and down. [referring to
graphs] cos you forget sometimes when your good
days are and your bad days. [P207]
Recommendations
While many of the participants described the symptoms graphs
as helpful, it was clear that the interpretation of the graphs
became more difficult as data entry increased. One respondent
also reported that the date of entry did not appear on the printout,
while other participants found the graphs difficult to view on a
smartphone. This is an area for attention in future versions of
the program.
The pilot study found that the resources page was accessed at
the beginning of the chemotherapy cycle but not much
thereafter. In phase 3, to encourage continued engagement with
the resources page, additional reminders were added to the daily
summary page:
Well there were links and information that you could
actually access direct from there. Sometimes I was
just too tired to follow it through. But when I was able
I appreciated the fact that the information was there.
So I’ve actually kept the stuff in mind to take action.
I’ve actually printed some of this stuff out so I know
what to do if I get a um, what to watch out for. [P218]
Several participants referred to forgetting to enter data or feeling
too ill to enter data. We added a button on the front page so that
participants could indicate that they hadn’t forgotten but did
not feel like completing the scales. Some participants suggested
the ability to enter data retrospectively would be valuable and
this could be a feature in a future version of the program.
The thing that I actually found the most frustrating
to be honest, was the fact that and especially initially
um you couldn’t go back. Like the first day I logged
in and I couldn’t actually go back to like the couple
of days before that and put in, like I’d noted down
what my symptom were but I couldn’t go back because
of it. Like you couldn’t do it for a specific date. I think
would’ve been helpful for you guys and for me. [P208]
During the pilot phase, we identified incorrect data entries when
participants forgot to move the slider, which had a default setting
of “5”, resulting in an amber alert. As a result, all sliders were
set to 0 as a starting point. Some participants suggested that it
would have been good if they had the ability to go back and
edit entered data, as sometimes the slider would land on a
number they didn’t intend to submit:
But again—also being able to edit it because
sometimes I accidentally pressed like it went to 10
because I scrolled up and I accidentally pressed it
not realizing yet because it would look like I’ve hit a
10 but I can’t go back and edit it. [P211]
Some participants asked for more information on specific issues,
including the use of pain killers, a specific focus on the first
week of treatment when symptoms were at their worst, and the
use of supplements:
Yeah. And painkillers as well because at the moment
I’m just going from one lot of pain killers to another
lot of pain killers and they don’t really tell you much
on the side effects…Or other supplements that can
be added like Sustagen and things like that. You know
I’ve had to remind myself I can take that. [P204]
Some participants suggested providing different daily messages:
Yeah definitely. I can’t remember what they say
exactly but from memory it was just the first time I
read it either. Yeah. And then I noticed after a few
days was the same thing so I just I was okay with that.
And when it changed color I read it again. Come on.
OK it’s like something different again. I think that,
like I said before the more personable thing that’s
definitely something to look at. [P211]
Participants suggested that setting up the program as an app
would be helpful in relation to accessing the program directly
from their smartphone and the ability of the app to generate
push notifications as reminders to complete the symptom tracker.
Overall, participants reported positive experiences and many
believed the system has great potential to be further developed.
Discussion
Principal Results
Our results demonstrated that participants involved in this study
were positive about their experience of using SAM to monitor
and manage their chemotherapy-related symptoms. Participants
found SAM to be helpful in supporting them to manage
symptoms and described feeling confident in accessing and
using the site. Participants reported that using SAM increased
feelings of reassurance and security related to awareness of
symptoms and changes on a daily basis. The generation of an
alert when symptoms were moderate or high was
overwhelmingly viewed as positive by participants, who
described acting on the advice given, and participants were
impressed when the oncology team followed up with them. The
interactive aspects of SAM highlight the ability of technology
to be used for purposes beyond data collection. The system has
established procedures to both generate feedback and promote
early intervention. Based on their experiences, participants could
see potential for the development of SAM, in terms of both the
functionality of the system and developments within the health
care system. Suggestions for developments include the addition
of an alarm feature to remind participants to complete the
symptom scales, the ability to enter missed data and edit data
entered in error, and an option to allow the report of any
additional symptoms experienced that were not covered by the
core symptoms reported. The functionality of the system,
positive feedback from patients, and refinements of the system
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based on feedback from participants, consumers, and the
advisory group support recommendations for the further
development of the system and its use within health care
services.
Limitations
The limitations of the study include that it was set up as a pilot
study and as such the sample size was small and no comparison
group data were collected. Nearly one-half of the individuals
who were approached to participate declined. The most common
reason given was feeling overwhelmed with their diagnosis and
upcoming treatment. Data were collected over a limited time
period, and the role of a system like SAM over a longer time
period—even posttreatment—in the improvement in supportive
care needs remains an area for exploration. Participation was
restricted to 2 tumor groups and the applicability of the system
to people with similar symptom profiles is likely but cannot be
confirmed. Future research with a larger sample of patients
receiving adjuvant chemotherapy following breast or colorectal
cancer and a comparison group is recommended. Exploratory
studies to adapt the SAM system for people with advanced
disease and those receiving other treatment modalities (eg,
immunotherapy) are recommended.
Conclusions
This study indicated that people receiving postoperative
chemotherapy for breast or colorectal cancer had positive
perceptions of and experiences using SAM to monitor and
manage chemotherapy-related toxicity. The remote monitoring
of symptoms and an alerting system helped to ensure that people
who were experiencing symptoms were identified early and that
participants were facilitated to seek timely intervention. This
has the potential to reduce both the severity and duration of the
symptoms experienced, promoting a system of care that is
anticipatory and preventative rather than reactive. This serves
to enhance patient safety as a direct line of communication
between the patient, cancer specialists, and the general
practitioner, and provides patients with access to evidence-based,
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